| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Dermatology [X. Z., R. A.] and Molecular Biology and Microbiology [A. W. G., H-J. K.], Skin Diseases Research Center and Case Western Reserve University Ireland Cancer Center University Hospitals of Cleveland [H-J. K., R. A.], Case Western Reserve University, Cleveland, Ohio 44106, and Center for Cancer Causation and Prevention, AMC Cancer Research Center, Denver, Colorado 80214 [R. A.]
Prostate cancer (PCA) is the most common nonskin malignancy and the second leading cause of cancer deaths in United States males. One practical and translational approach to control PCA is to define a mechanism-based anticarcinogenic agent(s). Recently, we showed that silymarin, a flavonoid antioxidant isolated from milk thistle, possesses exceptionally high to complete protective effects against experimentally induced tumor-igenesis. Because the epidermal growth factor receptor (erbB1) and other members of the erbB family have been shown to play important roles in human PCA, efforts should be directed to identify inhibitors of this pathway for PCA intervention. In this study, we assessed whether silymarin inhibits erbB1 activation and associated downstream events and modulates cell cycle regulatory proteins and progression, leading to growth inhibition of human prostate carcinoma DU145 cells. Treatment of serum-starved cells with silymarin resulted in a significant inhibition of transforming growth factor 
-mediated activation of erbB1 but no change in its protein levels. Silymarin treatment of cells also resulted in a significant decrease in tyrosine phosphorylation of an immediate downstream target of erbB1, the adapter protein SHC, together with a decrease in its binding to erbB1. In the studies analyzing cell cycle regulatory molecules, silymarin treatment of cells also resulted in a significant induction of cyclin-dependent kinase inhibitors (CDKIs) Cip1/p21 and Kip1/p27, concomitant with a significant decrease in CDK4 expression, but no change in the levels of CDK2 and CDK6 and their associated cyclins E and D1, respectively. Cells treated with silymarin also showed an increased binding of CDKIs with CDKs, together with a marked decrease in the kinase activity of CDKs and associated cyclins. In additional studies, treatment of cells grown in 10% serum with anti-epidermal growth factor receptor monoclonal antibody clone 225 or different doses of silymarin also resulted in significant inhibition of constitutive tyrosine phosphorylation of both erbB1 and SHC but no change in their protein levels. Furthermore, whereas silymarin treatment resulted in a significant increase in the protein levels of both Cip1/p21 and Kip1/p27, monoclonal antibody 225 showed an increase only in Kip1/p27. These findings suggest that silymarin also inhibits constitutive activation of erbB1 and that the observed effect of silymarin on an increase in CDKI protein levels is mediated via inhibition of erbB1 activation only in the case of Kip1/p27; however, additional pathways independent of inhibition of erbB1 activation are possibly responsible for the silymarin-caused increase in Cip1/p21 in DU145 cells. In other studies, silymarin treatment also induced a G1 arrest in the cell cycle progression of DU145 cells and resulted in a highly significant to complete inhibition of both anchorage-dependent and anchorage-independent growth of DU145 cells in a dose- and time-dependent manner. Taken together, these results suggest that silymarin may exert a strong anticarcinogenic effect against PCA and that this effect is likely to involve impairment of erbB1-SHC-mediated signaling pathway, induction of CDKIs, and a resultant G1 arrest.
1 This work was supported in part by United States Public Health Service Grant CA 64514 (to R. A.), a Prostate Cancer pilot grant from Case Western Reserve University Cancer Center through the funds provided by United States Public Health Service Grant P30-CA 43703, and an Ohio Cancer Research Associates grant.
2 To whom requests for reprints should be addressed, at the Center for Cancer Causation and Prevention, AMC Cancer Research Center, 1600 Pierce Street, Denver, CO 80214. Phone: (303) 239-3580; Fax: (303) 239-3560; E-mail: agarwalr@amc.org.
Received 11/11/97. Accepted 3/ 4/98.
This article has been cited by other articles:
|
|
 |
|
  M. Kaur, B. Velmurugan, A. Tyagi, G. Deep, S. Katiyar, C. Agarwal, and R. Agarwal Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft Mol. Cancer Ther., August 1, 2009; 8(8): 2366 - 2374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Singh, K. Raina, G. Sharma, and R. Agarwal Silibinin Inhibits Established Prostate Tumor Growth, Progression, Invasion, and Metastasis and Suppresses Tumor Angiogenesis and Epithelial-Mesenchymal Transition in Transgenic Adenocarcinoma of the Mouse Prostate Model Mice Clin. Cancer Res., December 1, 2008; 14(23): 7773 - 7780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-F. Wu, S.-L. Fu, C.-H. Kao, C.-W. Yang, C.-H. Lin, M.-T. Hsu, and T.-F. Tsai Chemopreventive Effect of Silymarin on Liver Pathology in HBV X Protein Transgenic Mice Cancer Res., March 15, 2008; 68(6): 2033 - 2042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Raina, M.-J. Blouin, R. P. Singh, N. Majeed, G. Deep, L. Varghese, L. M. Glode, N. M. Greenberg, D. Hwang, P. Cohen, et al. Dietary Feeding of Silibinin Inhibits Prostate Tumor Growth and Progression in Transgenic Adenocarcinoma of the Mouse Prostate Model Cancer Res., November 15, 2007; 67(22): 11083 - 11091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Roy, M. Kaur, C. Agarwal, M. Tecklenburg, R. A. Sclafani, and R. Agarwal p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells Mol. Cancer Ther., October 1, 2007; 6(10): 2696 - 2707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Deep and R. Agarwal Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer Integr Cancer Ther, June 1, 2007; 6(2): 130 - 145. [Abstract] [PDF]
|
|
|
|
|
|
M. Provinciali, F. Papalini, F. Orlando, S. Pierpaoli, A. Donnini, P. Morazzoni, A. Riva, and A. Smorlesi Effect of the Silybin-Phosphatidylcholine Complex (IdB 1016) on the Development of Mammary Tumors in HER-2/neu Transgenic Mice Cancer Res., March 1, 2007; 67(5): 2022 - 2029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Malewicz, Z. Wang, C. Jiang, J. Guo, M. P. Cleary, J. P. Grande, and J. Lu Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements Carcinogenesis, September 1, 2006; 27(9): 1739 - 1747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hoh, D. Boocock, T. Marczylo, R. Singh, D. P. Berry, A. R. Dennison, D. Hemingway, A. Miller, K. West, S. Euden, et al. Pilot Study of Oral Silibinin, a Putative Chemopreventive Agent, in Colorectal Cancer Patients: Silibinin Levels in Plasma, Colorectum, and Liver and Their Pharmacodynamic Consequences. Clin. Cancer Res., May 1, 2006; 12(9): 2944 - 2950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Varghese, C. Agarwal, A. Tyagi, R. P. Singh, and R. Agarwal Silibinin Efficacy against Human Hepatocellular Carcinoma Clin. Cancer Res., December 1, 2005; 11(23): 8441 - 8448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kohno, R. Suzuki, S. Sugie, H. Tsuda, and T. Tanaka Dietary Supplementation with Silymarin Inhibits 3,2'-Dimethyl-4-Aminobiphenyl-Induced Prostate Carcinogenesis in Male F344 Rats Clin. Cancer Res., July 1, 2005; 11(13): 4962 - 4967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Traver, B. Salthun-Lassalle, M. Marien, E. C. Hirsch, F. Colpaert, and P. P. Michel The Neurotransmitter Noradrenaline Rescues Septal Cholinergic Neurons in Culture from Degeneration Caused by Low-Level Oxidative Stress Mol. Pharmacol., June 1, 2005; 67(6): 1882 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhang, S.-M. Huong, X. Wang, D. Y. Huang, and E.-S. Huang Interactions between Human Cytomegalovirus IE1-72 and Cellular p107: Functional Domains and Mechanisms of Up-Regulation of Cyclin E/cdk2 Kinase Activity J. Virol., December 1, 2003; 77(23): 12660 - 12670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Singh, G. Sharma, S. Dhanalakshmi, C. Agarwal, and R. Agarwal Suppression of Advanced Human Prostate Tumor Growth in Athymic Mice by Silibinin Feeding Is Associated with Reduced Cell Proliferation, Increased Apoptosis, and Inhibition of Angiogenesis Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 933 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Brar, Z. Corbin, T. P. Kennedy, R. Hemendinger, L. Thornton, B. Bommarius, R. S. Arnold, A. R. Whorton, A. B. Sturrock, T. P. Huecksteadt, et al. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells Am J Physiol Cell Physiol, August 1, 2003; 285(2): C353 - C369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Singh, C. Agarwal, and R. Agarwal Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes Carcinogenesis, March 1, 2003; 24(3): 555 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Brown, J. O'Prey, and P.R. Harrison Enhanced sensitivity of human oral tumours to the flavonol, morin, during cancer progression: involvement of the Akt and stress kinase pathways Carcinogenesis, February 1, 2003; 24(2): 171 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gopalakrishna and U. Gundimeda Antioxidant Regulation of Protein Kinase C in Cancer Prevention J. Nutr., December 1, 2002; 132(12): 3819S - 3823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Tyagi, R. P. Singh, C. Agarwal, D. C. F. Chan, and R. Agarwal Silibinin Strongly Synergizes Human Prostate Carcinoma DU145 Cells to Doxorubicin-induced Growth Inhibition, G2-M Arrest, and Apoptosis Clin. Cancer Res., November 1, 2002; 8(11): 3512 - 3519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Singh, S. Dhanalakshmi, A. K. Tyagi, D. C. F. Chan, C. Agarwal, and R. Agarwal Dietary Feeding of Silibinin Inhibits Advance Human Prostate Carcinoma Growth in Athymic Nude Mice and Increases Plasma Insulin-like Growth Factor-binding Protein-3 Levels Cancer Res., June 1, 2002; 62(11): 3063 - 3069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yanaida, H. Kohno, K. Yoshida, Y. Hirose, Y. Yamada, H. Mori, and T. Tanaka Dietary silymarin suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats Carcinogenesis, May 1, 2002; 23(5): 787 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tyagi, C. Agarwal, and R. Agarwal Inhibition of Retinoblastoma Protein (Rb) Phosphorylation at Serine Sites and an Increase in Rb-E2F Complex Formation by Silibinin in Androgen-dependent Human Prostate Carcinoma LNCaP Cells: Role in Prostate Cancer Prevention Mol. Cancer Ther., May 1, 2002; 1(7): 525 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Singh, A. K. Tyagi, J. Zhao, and R. Agarwal Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis Carcinogenesis, March 1, 2002; 23(3): 499 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Don, Y.-H. Chang, K.-K. Chen, L.-K. Ho, and Y.-P. Chau Induction of CDK Inhibitors (p21WAF1 and p27Kip1) and Bak in the {beta}-Lapachone-Induced Apoptosis of Human Prostate Cancer Cells Mol. Pharmacol., April 1, 2001; 59(4): 784 - 794. [Abstract] [Full Text]
|
|
|
|
|
|
X. Zi, R. P. Singh, and R. Agarwal Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells Carcinogenesis, December 1, 2000; 21(12): 2225 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zi, J. Zhang, R. Agarwal, and M. Pollak Silibinin Up-Regulates Insulin-like Growth Factor-Binding Protein 3 Expression and Inhibits Proliferation of Androgen-independent Prostate Cancer Cells Cancer Res., October 1, 2000; 60(20): 5617 - 5620. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. K. Manna, A. Mukhopadhyay, N. T. Van, and B. B. Aggarwal Silymarin Suppresses TNF-Induced Activation of NF-{kappa}B, c-Jun N-Terminal Kinase, and Apoptosis J. Immunol., December 15, 1999; 163(12): 6800 - 6809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhao and R. Agarwal Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention Carcinogenesis, November 1, 1999; 20(11): 2101 - 2108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhao, J. Wang, Y. Chen, and R. Agarwal Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation–promotion protocol and identification of procyanidin B5-3'-gallate as the most effective antioxidant constituent Carcinogenesis, September 1, 1999; 20(9): 1737 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zi and R. Agarwal Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention PNAS, June 22, 1999; 96(13): 7490 - 7495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Putz, Z. Culig, I. E. Eder, C. Nessler-Menardi, G. Bartsch, H. Grunicke, F. Uberall, and H. Klocker Epidermal Growth Factor (EGF) Receptor Blockade Inhibits the Action of EGF, Insulin-like Growth Factor I, and a Protein Kinase A Activator on the Mitogen-activated Protein Kinase Pathway in Prostate Cancer Cell Lines Cancer Res., January 1, 1999; 59(1): 227 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Stivala, M. Savio, F. Carafoli, P. Perucca, L. Bianchi, G. Maga, L. Forti, U. M. Pagnoni, A. Albini, E. Prosperi, et al. Specific Structural Determinants Are Responsible for the Antioxidant Activity and the Cell Cycle Effects of Resveratrol J. Biol. Chem., June 15, 2001; 276(25): 22586 - 22594. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
